Evidence map›Paper›PMID 42733720›Full record

ArticleInfectious medicine2026

Discovery of human antibody specific to the spike glycoprotein subunit 2 of SARS-CoV-2 and characterization of its broad-spectrum neutralizing activity.

Ying Chi, Huimin Yin, Chao Huang, Yiyue Ge, Jingxian Liu, Yuhan Ding, Fengjuan Shi, Zhou Cui, Shuo Ning, Yongjun Jiao and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infectious medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ying ChiNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Medical Key Laboratory of Pathogenic Microbiology in Emerging Major Infectious Diseases, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, 210009, China.
Huimin YinDepartment of Clinical Nutrition, Taikang Xianlin Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210046, China.
Chao HuangNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Medical Key Laboratory of Pathogenic Microbiology in Emerging Major Infectious Diseases, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, 210009, China.
Yiyue GeNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Medical Key Laboratory of Pathogenic Microbiology in Emerging Major Infectious Diseases, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, 210009, China.
Jingxian LiuNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Medical Key Laboratory of Pathogenic Microbiology in Emerging Major Infectious Diseases, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, 210009, China.
Yuhan DingNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Medical Key Laboratory of Pathogenic Microbiology in Emerging Major Infectious Diseases, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, 210009, China.
Fengjuan ShiNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Medical Key Laboratory of Pathogenic Microbiology in Emerging Major Infectious Diseases, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, 210009, China.
Zhou CuiNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Medical Key Laboratory of Pathogenic Microbiology in Emerging Major Infectious Diseases, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, 210009, China.
Shuo NingNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Medical Key Laboratory of Pathogenic Microbiology in Emerging Major Infectious Diseases, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, 210009, China.
Yongjun JiaoNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Medical Key Laboratory of Pathogenic Microbiology in Emerging Major Infectious Diseases, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, 210009, China.
Lunbiao CuiNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Medical Key Laboratory of Pathogenic Microbiology in Emerging Major Infectious Diseases, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, 210009, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve and mutate during transmission, making the development of effective broad-spectrum antibodies for the prevention and treatment of SARS-CoV-2 infections of great significance. In this study, peripheral blood mononuclear cells were isolated from 15 convalescent coronavirus disease 2019 (COVID-19) patients to construct a human-derived single-chain variable fragment (scFv) antibody library against SARS-CoV-2. Monoclonal antibodies targeting the conserved structural region of the spike glycoprotein subunit 2 (S2) protein with broad-spectrum neutralizing activity were subsequently screened. Methods: The cDNA of the peripheral blood mononuclear cells from 15 convalescent COVID-19 patients was used to amplify the human-derived antibody heavy chain variable region (VH) and light chain variable region (VL) via polymerase chain reaction (PCR). The VH and VL genes were randomly assembled into scFvs using overlap extension PCR. The constructed scFv gene library was cloned into the phage display vector pComb3XSS and electroporated into XL1-Blue cells to generate a human SARS-CoV-2 scFv antibody library. Then monoclonal antibodies specific to the SARS-CoV-2 S2 domain were screened by phage display. Gene sequencing and recombinant human immunoglobulin G (IgG) monoclonal antibody expression were performed to produce human IgG antibody. The antibody was subsequently evaluated for its binding ability and neutralizing activity against different viral subtypes. Furthermore, the fragment antigen-binding region of the selected antibody was modeled using structure prediction tools to support subsequent structural analysis. Results: The library size of the constructed human-derived SARS-CoV-2 scFv library is 1.6 × 10⁷ CFU. The S2-specific full-length IgG antibody was selected and expressed, which demonstrated neutralizing activity against both the SARS-CoV-2 wild type strain and the Omicron variant. Conclusions: A human single-chain antibody library against SARS-CoV-2 was successfully constructed. From this library, a human antibody targeting the highly conserved S2 region of SARS-CoV-2 was selected, which exhibited broad-spectrum neutralizing activity. This antibody shows potent

Indexed as

Human scFv libraryNeutralizing antibodySevere acute respiratory syndrome coronavirus 2Spike glycoprotein subunit 2

Identifiers

PMID42733720
PMCPMC13571484

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.